

26 April 2019

Eye Co Announces Patent Filing Relating to the use of Hemp Extract and Method of Treatment or Prevention of Age-Related Macular Degeneration

Eye Co is pleased to confirm that it has filed a PCT application relating to the composition and treatment of Age-Related Macular Degeneration (AMD) with hemp, hemp seed oil or a pharmaceutical active extract thereof.

The patent application is directed to methods of treating or preventing AMD by providing therapeutically active amounts of hemp, hemp seed oil or pharmaceutically effective extracts of hemp seed oil. The use of compositions comprising hemp seed oil as a carrier of pharmaceutical actives intended for intravitreal administration, is also covered by this patent application.

The patent filing follows pre-clinical studies using the previously announced mouse models at the Australian National University (ANU). ANU's mouse model develops a AMD-like lesion, that results from exposure to bright light, and is known to be mediated by the 'complement pathway' of the immune system - as occurs in human disease. The lesion is anatomically and immunologically consistent with the human condition.

Eye Co's Chief Scientist, Professor Philip Penfold said: "These studies support the use of hemp seed oil as carrier for intravitreal steroids and other pharmaceutical actives."

Eye Co is an early stage developer of innovative therapeutics for the treatment of retinal diseases. The filing of this patent, which once granted will provide patent rights until the year 2038, is consistent with its strategy of initiating early stage development of innovative treatments with the intention of licensing the associated intellectual property to a global pharmaceutical group with the necessary resources to commercialise such innovations.

Your sincerely



Peter Abrahamson FAICD
Managing Director